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Abstract
Acute myeloid leukemia (AML) results from multiple genetic and epigenetic aberrations, many of which remain unidentified.
Frequent loss of large chromosomal regions marks haplo-insufficiency as one of the major mechanisms contributing to
leukemogenesis. However, which haplo-insufficient genes (HIGs) are involved in leukemogenesis is largely unknown and
powerful experimental strategies aimed at their identification are currently lacking. Here, we present a new approach to
discover HIGs, using retroviral integration mutagenesis in mice in which methylated viral integration sites and neighbouring
genes were identified. In total we mapped 6 genes which are flanked by methylated viral integration sites (mVIS). Three of
these, i.e., Lrmp, Hcls1 and Prkrir, were up regulated and one, i.e., Ptp4a3, was down regulated in the affected tumor. Next,
we investigated the role of PTP4A3 in human AML and we show that PTP4A3 expression is a negative prognostic indicator,
independent of other prognostic parameters. In conclusion, our novel strategy has identified PTP4A3 to potentially have a
role in AML, on one hand as a candidate HIG contributing to leukemogenesis in mice and on the other hand as a prognostic
indicator in human AML.
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Introduction
Acute myeloid leukemia (AML) is a complex disease driven by
multiple cytogenetic abnormalities, such as inv(16), t(8;21),
t(15;17), 3q abnormalities, deletions of (the q-arms) of chromo-
some 5 and 7 and by aberrant expression and/or mutations of
genes e.g., EVI1, FLT3, RAS, RUNX1, CKIT, WT1, CEBPA and
NPM1 [1,2]. The frequent occurrence of chromosomal deletions
suggests that haplo-insufficiencies contribute to the pathogenesis of
AML. However, because deleted regions often harbor numerous
genes, it remains difficult to pin point critical haplo-insufficient
genes (HIGs) involved in the pathogenesis of AML. Gene
expression profiling (GEP) focusing on down regulated genes
could be informative, however differences in expression levels may
relate to differentiation status of the AML blasts, rather than to
mechanisms underlying leukemogenesis [3]. In addition, mapping
of minimal affected regions in combination with GEP to identify
HIGs often is cumbersome because these regions may still contain
numerous genes and differences in their expression level may be
subtle. Even in chromosomal regions frequently lost upon
leukemic progression, e.g., the q-arm of chromosome 7, identifi-
cation of critical HIGs remains difficult.
Retroviral insertion mutagenesis in mouse models has been used
to discover novel genes involved in the development of different
types of cancer [4,5,6]. Most of these genes have been classified as
proto-oncogenes, owing to the fact that proviral integrations
preferentially occur in 59 promoter regions, supposedly leading to
increased or sustained expression of flanking genes. Only a small
minority of identified genes have been classified as tumor
suppressor genes or HIGs, based on disruption of coding
sequences by the proviral integration [7,8]. Gene therapy studies
using murine leukemia virus (MLV)-based vectors have shown that
epigenetic changes of long terminal repeats (LTRs) of integrated
proviruses often result in silencing of therapeutic genes [9,10], and
that preventing methylation of the CpG islands within LTRs
overcomes this problem [11]. Based on these observations, we
hypothesized that methylation of viral sequences not only results in
silencing of retroviral genes themselves but may also affect host
genes located proximal to proviral integrations. Methylated LTRs
located in proximity of promoter regions may thus identify genes
that are deregulated leading to haplo-insufficiency.
To discover potential HIGs relevant for human AML, we used
murine leukemia samples induced by Graffi 1.4 Murine Leukemia
Virus (Gr1.4 MLV), classified as mixed lineage or myeloid
leukemias by immunophenotyping [6,12]. By methylation specific
PCR (MSP) and methylated DNA immunoprecipitation (MeDIP)
[13] we observed an extensive variation in the level of DNA
methylated proviral integrations in these tumors. We designed a
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strategy to map methylated proviral integrations by combining
MeDIP, inverse PCR (iPCR) and promoter array hybridization.
We identified 6 genes to be flanked by methylated viral integration
sites (mVIS), of which Lrmp, Hcls1 and Prkrir were transcriptionally
up regulated and Ptp4a3 was transcriptionally down regulated.
Further studies in human AML samples revealed a negative
prognostic value of PTP4A3 expression levels, independent of
other prognostic indicators. In conclusion, by mapping DNA
methylated viral integration sites in murine leukemias induced by
retroviral integration mutagenesis followed by comparative
analysis in human AML, we identified PTP4A3 not only as a
candidate HIG contributing to leukemogenesis in mice but also as
an independent prognostic indicator in human AML.
Results
Viral integrations sites of the Graffi1.4 MuLV are subject
to DNA methylation
In this study murine leukemia samples induced by Gr1.4 MLV
were analysed [6]. First, a methylation specific PCR (MSP) was
performed to determine the level of DNA methylation of the Gr1.4
MLV LTRs. To this end, amplification products from methylated
LTRs were quantified with quantitative PCR (qPCR) and
corrected for total LTRs in these samples (Figure 1A). A
considerable variation in LTR methylation was seen between
different tumors (data not shown). Based on these methylation
levels, leukemia samples were divided into 4 methylation
categories of equal sample size (1 = highest LTR methylation
level, 4 = lowest LTR methylation level).
Subsequently, MeDIP was used on a subset of samples to enrich
for methylated LTRs and flanking genomic regions. As a control,
genomic DNA of normal bone marrow, spleen and liver was used.
MeDIP enrichment relative to input levels was determined for the
LTR, the non-methylated actin B locus (ActB) and the hemi-
methylated imprinting control region 1 (ICR1) of H19. As
expected, H19 enrichment scores were high and ActB enrichment
scores were low in all categories (Figure 1B). Additionally, samples
in the highest methylation category showed a significantly higher
LTR enrichment after MeDIP compared to the samples in other
categories (p-value ,0.001), confirming the specificity of the MSP
(Figure 1B).
Ptp4a3 is flanked by a methylated viral integration site
and is transcriptionally down regulated
Genes located near methylated viral integration sites (mVIS) may
be down regulated due to the proximity of a methylated regulatory
sequence, and, their transcriptional down regulation may contribute
to murine leukemogenesis. Therefore, after showing that a
proportion of viral integration sites are subject to DNAmethylation,
we set out to identify genes flanking these viral integration sites. To
this end, iPCR, to amplify regions flanking viral integration sites,
and MeDIP, to enrich for DNA methylated fragments, were
combined to amplify regions flanking mVIS (Figure 2). Amplified
fragments of 6 tumor samples were hybridized to Murine 1.0 R
promoter arrays and, using hypergeometric analysis of tiling arrays
(HAT) [14], 15 amplified regions were mapped in these tumors
(Table S1). Eight of these integrations were validated by directed
PCR followed by Sanger sequencing (Figure 3, Table S1). Because
MLVs tend to integrate within 10 kb around the transcriptional
start site [15], the nearest genes within 10 kb downstream of these
8 mVIS were determined (Figure 3, Table S1).
To support that regions identified in this way were indeed
flanked by methylated LTRs, we performed a methylation
sensitive digestion followed by directed PCR. Using this approach,
only viral integration sites flanked by methylated LTRs could be
amplified (Figure 4A), as was the case for 6 out of 8 identified
integrations (Figure 4B, Table S1). Subsequently, expression levels
of genes flanking these mVIS were quantified by qPCR and
Figure 1. LTR methylation analysis. (A) Overview of the methylation specific PCR (MSP) approach. Depicted is a schematic representation of the
Gr1.4 MuLV LTR, containing 23 CpGs. The MSP was performed, after bisulphite treatment, with a methylation neutral forward primer (MN-LTR-fw), and
a methylation specific (MS-LTR-rv) or neutral (MN-LTR-rv) reverse primer. Amplification products were quantified using methylation neutral probe-
MN. Tumor samples were divided into 4 equal groups based on the methylation status of their LTRs (1 = highest LTR methylation level, 4 = lowest LTR
methylation level). (B) Left panel. For H19, the LTR and ActB, average enrichment after MeDIP compared to input levels were calculated for each MSP-
defined methylation category as well as for normal bone marrow, spleen and liver (N). In category 1 to 4 respectively 18, 15, 4 and 3 samples were
analysed; error bars indicate standard deviations. P-values were calculated using a Wilcoxon test; *significantly higher than other categories, p-value
,0.001. Right panel. Example of LTR enrichment after MeDIP (I = input, += IP with anti-5-methylcytidine, 2= IP with pre-immune serum IgG, 1 and
3=methylation categories, N =normal spleen).
doi:10.1371/journal.pone.0026537.g001
PTP4A3 Expression Is a Prognostic Indicator in AML
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26537
compared to normal bone marrow expression levels. Unfortu-
nately, RNA of tumor 1 was lacking, therefore this analysis could
not be performed for Taf12 and Ranbp3. Of the other 4 genes,
Ptp4a3 expression was 2–3 fold reduced in the respective tumor
(Figure 4C, Table S1).
Ptp4a3 is an independent prognostic factor in human
AML
The human orthologue of murine Ptp4a3, i.e., PTP4A3, was
further studied in human AML. Transcript levels of PTP4A3 were
assessed in 454 AML samples, diagnosed under the age of 60,
profiled using the HGU133 2.0 plus gene expression arrays [16].
PTP4A3 expression values are represented by 2 probesets with a
high correlation (Pearson correlation coefficient = 0.90). Survival
analysis with these probesets gave similar results; all results shown
are based on expression levels of probeset 206574_s_at. PTP4A3
expression levels were negatively correlated with prognostic
outcome both for overall survival (OS, p-value ,0.0001, hazard
ratio = 1.269) and event-free survival (EFS, p-value ,0.0001,
hazard ratio = 1.261). Kaplan-Meier curves are shown in Figure 5.
A permutation test predicted a probability of 0.0036 for a random
gene locus to be a significant prognostic indicator with a p-value
,0.0001 for both OS and EFS. Multivariate analysis showed that
the negative correlation of PTP4A3 expression with event-free
survival was independent of other prognostic parameters, i.e., age,
white blood cell count, cytogenetic risk, CEBPA mutation status
and NPM1+FLT3ITD2 status (Table 1).
Discussion
We designed a strategy to identify candidate HIGs in AML
using retroviral integration mutagenesis, by mapping DNA
methylated proviral integrations. By using HAT [14], we
deliberately aimed at detecting integrations present in the majority
of the leukemic cells, which are most likely involved in the early
phase of leukemogenesis. At the same time, integrations present in
subclones that contribute to later stages of leukemic progression
will be missed using this approach. We identified 6 genes that are
flanked by methylated viral integrations. Expression analysis
showed that Lrmp (lymphoid-restricted membrane protein), Hcls1
(hematopoietic cell specific Lyn substrate 1) and Prkrir (protein-
kinase, interferon-inducible double stranded RNA dependent
inhibitor, repressor of (P58 repressor)) were up regulated and
Ptp4a3 (protein tyrosine phosphatase type IVA), a phosphatase also
known as Prl3 (phosphatase of regenerating liver 3) was down
regulated in the respective murine tumor. These results indicate
that a flanking methylated viral integration site does not
necessarily lead to transcriptional repression. As 1 out of 4 genes
flanked by a mVIS was transcriptionally down regulated and
expression of the 2 other genes could not be investigated, the
efficiency to detect potential HIGs by identifying mVIS would
approximately be 17–25%. However, the number of analysed
tumors is too small to allow an accurate estimation of the
efficiency.
Ptp4a3 expression is controlled by p53 induced after DNA
damage in mouse embryonic fibroblasts (MEFs) and its activity is
involved in inducing a G1 cell cycle arrest in these cells [17].
Surprisingly however, the same study also demonstrated a cell
cycle arrest upon reduction of PTP4A3 expression [17]. Appar-
ently, depending on expression level dosage, PTP4A3 may have
both positive and negative effects on cell cycle regulation. Hence,
PTP4A3 haplo-insufficiency, but not its complete loss, may lead to
an impairment of cell cycle arrest after DNA damage. Dosage
effects of PTP4A3 expression in relation to cellular responses may
Figure 2. Identification of mVIS. Strategy outline for identification of regions flanking DNA methylated viral integration sites (mVIS) within murine
leukemias. Genomic DNA was digested with DpnII (step 1), followed by methylated DNA immunoprecipitation (MeDIP, step 2). MeDIP enriched
fragments were ligated (step 3) and amplified using primers within the LTR (step 4). These fragments were hybridized on a DNA promoter array (step
5). Hypergeometric Analysis of Tiling Arrays (HAT) was used to identify regions flanking mVIS (step 6).
doi:10.1371/journal.pone.0026537.g002
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be more complex, particularly in cancer cells. For example, in
carcinoma cell lines PTP4A3 expression may lead to down
regulation of p53 [18] and it is variably induced by c-irradiation
[19]. Finally, high PTP4A3 expression has been linked to increased
tumor aggressiveness in different types of solid tumors, e.g.,
melanoma, gastric cancer, colon cancer, hepatocellular carcinoma
and breast cancer [20,21,22,23,24], possibly because high PTP4A3
expression leads to increased epithelial-mesenchymal transition
[25].
The role of PTP4A3 in hematopoietic malignancies has not
been studied as extensively as in carcinoma. Only a few studies
report differences in expression levels of PTP4A3 in ALL and
myeloma subgroups, based on gene expression profiling
[26,27,28]. Interestingly however, in a recent study, PTP4A3 has
been proposed to have a role in drug-resistance in AMLs with
internal tandem duplication of FLT3 (FLT3ITD) [29]. This
finding, together with the observation that high PTP4A3
expression negatively correlates with prognostic outcome, indicates
that PTP4A3 might be a potential therapeutic target in AML.
In conclusion, using a retroviral mutagenesis screen in which we
enriched for DNA methylated viral integration sites we identified
PTP4A3 as a potential haplo-insufficient gene with an independent
prognostic value in human de novo AML. Challenges for the
future are to determine the dose-effect of PTP4A3 expression in
myeloid development and to extend the screens to additional
myeloid neoplasms, e.g., myelodysplasia, therapy-related AML,
AML secondary to bone marrow failure and myeloproliferative
disorders.
Materials and Methods
Ethics statement
For this study no novel murine leukemias were generated, all
experiments described were performed on material generated in a
previous study [6]. All animal procedures for the use of control
bone marrow fractions were approved by the animal care and use
committee of the Erasmus MC (approval # 119-10-05).
All human cell samples were obtained after written informed
consent and stored anonymously in a biobank. The study was
performed under the permission of the Institutional Review Board
of the Erasmus MC, registration number MEC-2008-387.
Mouse leukemia and normal cell samples
DNA and RNA samples from a previously generated panel of
Gr1.4-induced leukemia’s [6], and control samples (bone marrow,
spleen, liver) from normal FVB/N mice were used.
Figure 3. Identified viral integration sites. Eight viral integrations identified with HAT could be confirmed with directed PCR and Sanger
sequencing (see Table S1 for further details). The graphical output of HAT is represented in graph A–H. Above each graph, the tumor in which the
integration was identified as well as the nearby located gene are indicated. The upper panel of each graph shows normalized intensities of the
different probes (blue lollipops) on the mouse promoter 1.0R arrays and their significance (in red) as calculated with HAT. The black arrowhead
indicates the exact position of the proviral integration, as determined by directed PCR followed by Sanger sequencing. In the lower panel the lowest
and highest probe intensity threshold with a significant outcome are given on the left. The stripes indicate significantly enriched regions at different
probe intensity thresholds, calculated with HAT, which are merged into the final viral integration site. Below each graph, the genomic position is
indicated (assembly mm8, February 2006).
doi:10.1371/journal.pone.0026537.g003
Figure 4. Methylation sensitive restriction analysis of viral integration sites and expression of nearby located genes. (A) Schematic
overview of the methylation specific restriction approach. Genomic DNA was digested with BstU1 (CGCG, blocked by DNA methylation), followed by
mVIS amplification with primers as indicated by arrows. If the flanking LTR is methylated, mVIS amplification is unaffected upon BstU1 digestion. (B)
All 8 identified viral integration sites, identified in tumor 1, 2 and 4, were amplified before (2) and after (+) BstU1 digestion. As controls, H19 (hemi-
methylated) and ActB (unmethylated), both containing 2 BstU1 digestion sites, were analysed in each tumor. (C) Expression levels of 4 genes flanked
by methylated viral integration sites were determined by qPCR in the respective tumors. Expression levels relative to housekeeping gene Tbp are
shown; error bars indicate standard deviations. NBM=normal bone marrow.
doi:10.1371/journal.pone.0026537.g004
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Methylation specific PCR
Primer and probe sequences are shown in Table S2. Two mg of
genomic DNA was treated with bisulphite using the EZ DNA
Methylation kit according to the manufacturer’s protocol (Zymo
research, Orange, CA, USA). LTRs were amplified with bsLTRfw
and bsLTRrv using 1 mL out of 10 mL of bisulphite-treated DNA.
Cycling conditions were 300 at 94uC, 300 at 50uC and 19 at 72uC
for 10 cycles in a total volume of 50 mL. Two mL was used in a
nested qPCR (Figure 1A) using MN-LTR-fw6MS-LTR-rv/MN-
LTR-rv (MN=methylation neutral, MS=methylation specific).
Cycling conditions were 150 at 94uC, 300 at 57uC and 300 at 60uC
for 45 cycles. Amplified LTRs, methylated and unmethylated,
were quantified using a methylation neutral probe (probe-MN,
Sigma-Aldrich, Zwijndrecht, The Netherlands). Delta cycle
threshold-values (dCt), representing the number of methylated
LTRs as a fraction of total LTRs, were calculated as follows:
dCt =Ct(Methylated LTRs)-Ct(All LTRs) =Ct(MN-LTR-fw6
MS-LTR-rv) – Ct(MN-LTR-fw6MN-LTR-rv). PCRs were per-
formed in duplicate and mean dCt values were calculated.
MeDIP
Ten mg genomic DNA was digested overnight with 100 U of
DpnII (New England Biolabs, Ipswich, MA, USA). Four mg
digested DNA was denatured for 109 at 95uC and incubated with
either 2.5 mg anti-5-methylcytidine (BI-MECY-1000, Eurogentec,
Lie`ge, Belgium) or mouse pre-immune IgG (Sigma-Aldrich,
Zwijndrecht, The Netherlands) in 500 mL IP-buffer (PBS with
0.05% Triton X-100) for 2 hrs at 4uC, followed by incubation with
30 mL of washed beads (M-280 sheep-anti-mouse IgG, Invitrogen,
San Diego, CA, USA) for 2 hrs at 4uC. Beads were washed 3 times
with 700 mL IP-buffer. As a 10% input reference, 400 ng digested
DNA not subjected to MeDIP was used. Beads and the 10% input
reference DNA were resuspended in 100 mL IP-buffer and
incubated for 3 hrs at 50uC after adding 20 mg proteinase K
(Roche, Basel, Switzerland). Supernatants, containing immuno-
precipitated DNA, and the input DNA were purified using the
MinElute Reaction Cleanup Kit (Qiagen, Hilden, Germany) and
were eluted in 40 mL elution buffer. Two mL immunoprecipitated
DNA was used to amplify the imprinting control region 1 (ICR1)
of H19 with H19ICR1fw 6 H19ICR1rv, ActB with ActBfw 6
ActBrv and the LTR with LTRfw6LTRrv using (q)PCR. Primer
sequences are shown in Table S2. Cycling conditions were 300 at
95uC, 300 at 58uC and 450 at 72uC for 30 cycles (PCR) or 150 at
94uC, 300 at 59uC and 300 at 60uC for 45 cycles (qPCR).
Amplification products were analysed using gel electrophoresis
(PCR) or quantified (qPCR) using SYBRgreen Master mix
(Applied Biosystems, Foster City, CA, USA).
Inverse PCR
Primer sequences are shown in Table S2. Six murine leukemias
with high LTR enrichment (more than 10% of input) and low ActB
enrichment (less than 10% of input) were selected for inverse PCR.
Eight mL MeDIP-DNA was denatured for 39 at 95uC, renatured
by a temperature decrease of 0.1uC/sec to 20uC, and ligated for
459 at room temperature using a rapid DNA ligation kit (Roche,
Basel, Schwitzerland). Two mL out of 20 ml ligated product was
amplified with primers mL1 and mL2, followed by a nested PCR
with primers mL1N and mL2N using 2 mL of the first PCR
product. Cycling conditions were 300 at 95uC, 300 at 60uC (first
PCR) or 56uC (nested PCR) and 39 at 72uC for 30 cycles. In the
nested PCR 10 mM dCTP, dATP, dGTP, 8 mM dTTP and
2 mM dUTPs were used.
Promoter array hybridization
PCR products of 10 nested PCR reactions were purified with a
PCR purification kit (Qiagen, Hilden, Germany) and pooled. A
total of 7.5 mg of these amplified fragments was fragmented and
labeled using the GeneChip WT Double-stranded DNA terminal
labeling kit (Affymetrix, Santa Clara, CA, USA). Fragmentation to
66 bp was checked on a Bioanalyser (Agilent, Santa Clara, CA).
Labeled DNA was hybridized to mouse promoter 1.0R arrays
(Affymetrix, Santa Clara, CA, USA) for 16 hrs at 45uC. Arrays
were washed with the FS_450_0001 protocol using the Fluidics
Station 450 (Affymetrix, Santa Clara, CA, USA), followed by
scanning. Probe values were normalized with model-based analysis
of tiling-arrays (MAT) [30] and mVIS were determined using
hypergeometric analysis of tiling arrays (HAT) [14], both for HAT
Figure 5. Survival analysis. A cohort of 454 de novo AML cases
diagnosed under the age of 60 was divided into 2 groups of equal size
based on MAS5 normalised expression of PTP4A3 (probe 206574_s_at).
Overall survival (A) and event-free survival (B) were analysed. P-values
were calculated with a log rank test.
doi:10.1371/journal.pone.0026537.g005
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and MAT default settings were used. Genes located nearby
amplified regions were identified using UCSC (assembly mm8,
Feb. 2006).
Directed PCR and Sanger sequencing
Primers are shown in Table S2; amplification of the integration
site was performed with VIS(corresponding gene)6LTRfw2, for Lrmp
a nested PCR was performed with VIS(Lrmp_nested)6LTRfw. As
input, 200 ng of the corresponding tumor DNA was used; cycling
conditions were 300 at 95uC, 300 at 58uC and 450 at 72uC for 30
cycles. Products were purified using the Multiscreen HTS 66-well
filtration system (Millipore, Billerica, MA, USA). Sanger sequenc-
ing was performed with primer LTRfw according to the
manufacturer’s protocol (Applied Biosystems, Foster City, CA,
USA).
Methylation sensitive restriction analysis
Primers are shown in Table S2. Two and a half mg of tumor
DNA was digested with 25 U of BstU1 (New England Biolabs,
Ipswich, MA, USA) o/n at 60uC, purified using the Multiscreen
HTS 66-well filtration system (Millipore, Billerica, MA, USA),
eluted in 30 ml and diluted to 50 ng/ml. Amplification of the
integration site was performed as described under directed PCR
and Sanger sequencing, with 100 instead of 200 ng input of DNA.
As controls H19 ICR1 (H19ICR1fw 6 H19ICR1rv) and ActB
(ActBfw6ActBrv) were amplified. Cycling conditions were 300 at
95uC, 300 at 58uC and 450 at 72uC for 30 cycles. Amplification
products were analysed using gel electrophoresis.
RNA isolation, cDNA preparation and qPCR
RNA of murine samples was isolated using Trizol (Invitrogen,
San Diego, CA) according to the manufacturer’s protocol. One mg
of RNA was used for cDNA preparation, using SuperScript II
Reverse Transcriptase (Invitrogen, San Diego, CA) according to
the manufacturer’s protocol. One ml cDNA was used as input for
the qPCR. Genes of interest were amplified with their respective
forward and reverse primers (Table S2), as an input control,
TATA box binding protein (Tbp) was analysed. Cycling conditions
were 30 at 95uC and 300 at 60uC for 45 cycles. Amplification
products were quantified using Fast SYBRgreen Master mix
(Applied Biosystems, Foster City, CA, USA). Expression levels
relative to Tbp were calculated.
Survival analysis human AML samples
Purified AML blasts were obtained following informed consent
as described [31]. Gene-expression profiles of 454 de novo AML
patients under the age of 60 were used for this analysis [16].
Expression levels were MAS5 normalised (Scaling factor 100),
values ,30 were set at 30, followed by log2 transformation.
For Ptp4a3, univariate and multivariate survival analyses were
performed using expression levels of probesets 206574_s_at or
209695_at in a Cox regression model. In the multivariate analysis
age, white blood cell count, cytogenetic risk group,
NPM1+FLT3ITD2 status and CEBPA mutation status were used
as additional prognostic parameters. We recognised the following
cytogenetic risk groups: favorable = t(15;17), inv(16) and t(8;21),
unfavorable = t(3;3), inv(3), 27/7q-, 25/5q-, complex karyotype,
t(11q23) except t(9;11), t(9;22) and t(6;9), intermediate = all other
cases with known cytogenetics. Kaplan-meier graphs were
generated by dividing the AML cohort in 2 groups of equal
sample size based on PTP4A3 expression of probe 206574_s_at.
Analyses were performed in SPSS (version 17, SPPS Inc, Chicago,
IL).
For the permutation test, all probesets with an annotated gene
symbol (based on HG-U133_Plus_2.na32.annot.csv, Affymetrix,
Santa Clara, CA, USA) were selected. Next probesets with
expression levels ,30 in all 454 patients were discarded, leaving a
total of 40720 probesets. The permutation test was performed by
randomly selecting 6 probesets (representing 6 mVIS), followed by
randomly selecting 1 out of these 6 probesets (representing 1 down
regulated gene). For this probeset a univariate Cox regression
analysis was performed for overall survival (OS) and event-free
survival (EFS). A p-value of,0.0001 (as observed for PTP4A3) was
considered significant. This analysis was repeated 100.000 times,
followed by calculating the frequency, i.e., probability, of
observing a significant p-value for both OS and EFS. Analyses
were performed in Matlab (version 2008b, Mathworks, Natick,
MA).
Supporting Information
Table S1 Retroviral integrations. Retroviral integrations
identified with HAT are listed. For each integration the murine
tumor and the genomic position are indicated as well as whether
the integration could be confirmed with directed PCR and Sanger
Table 1. Multivariate survival analysis.
Overall Survival Event-Free Survival
Risk factor HR (95% CI) P-value HR (95% CI) P-value
PTP4A3 expression 1.112 (0.995–1.243) 0.061 1.131 (1.019–1.255) 0.021*
Age (decades) 1.134 (1.024–1.256) 0.016* 1.068 (0.969–1.177) 0.186
WBC‘ 1.373 (1.063–1.773) 0.015* 1.296 (1.020–1.648) 0.034*
Favorable cytogenetic risk{ 0.376 (0.257–0.548) ,0.0001* 0.469 (0.335–0.658) ,0.0001*
Unfavorable cytogenetic risk{ 1.432 (1.059–1.935) 0.020* 1.507 (1.124–2.020) 0.006*
NPM1+FLT3ITD-{ 0.473 (0.317–0.705) 0.0002* 0.578 (0.398–0.839) 0.004*
CEBPA double mutant$ 0.591 (0.418–0.836) 0.003* 0.560 (0.384–0.815) 0.002*
Multivariate analysis in 454 de novo AML patients under the age of 60.
‘WBC higher than 206109/L versus lower than 206109/L,
{compared to intermediate cytogenetic risk,
{compared to no NPM1+FLT3ITD2,
$compared to no CEBPA double mutation.
*Statistically significant. HR = hazard ratio, CI = confidence interval, WBC=white blood cell count, FLT3ITD= internal tandem duplication of FLT3.
doi:10.1371/journal.pone.0026537.t001
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sequencing. For all integrations that could be confirmed, nearby
located genes are given, their distance to the retroviral integration
and whether the flanking viral integration was DNA methylated as
analysed by methylation sensitive restriction analysis. Finally, for
the 6 genes with a flanking DNA methylated viral integration site
is indicated if they were down regulated in the respective tumor.
(XLS)
Table S2 Primers and probes.
(XLS)
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